Cognitive reserve and AβI-42 in mild cognitive impairment (Argentina-Alzheimer’s disease neuroimaging initiative)

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 2599-2604

  Harris, Paula ^a,b   Suarez, Marcos Fernandez ^a   Surace, Ezequiel I ^a,b   Méndez, Patricio Chrem ^a   Martín, María Eugenia ^a   Clarens, María Florencia ^a   Tapajóz, Fernanda ^a,b   Russo, Maria Julieta ^a   Campos, Jorge ^a   Guinjoan, Salvador M ^a,b   Sevlever, Gustavo ^a   Allegri, Ricardo F ^a,b  

^a Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Alzheimer s disease; Amyloid; Biomarkers; Cerebrospinal fluid

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARGENTINIAN ACCENTUATION READING TEST; ARTICLE; BOSTON NAMING TEST; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL DEMENTIA RATING; CLOCK DRAWING TEST; COGNITION; COGNITIVE RESERVE; COGNITIVE RESERVE QUESTIONNAIRE; CONTROLLED STUDY; DISEASE SEVERITY; EDUCATION; EMPLOYMENT STATUS; FEMALE; HUMAN; LEISURE; LUMBAR PUNCTURE; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MONTREAL COGNITIVE ASSESSMENT; MULTILINGUALISM; NERVE DEGENERATION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PSYCHOLOGIC TEST; QUESTIONNAIRE; REY AUDITORY VERBAL LEARNING TEST; RISK FACTOR; SCORING SYSTEM; TASK PERFORMANCE;

EID: 84943765749     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S84292     Document Type: Article

References (37)

1. Khachaturian ZS. Diagnosis of Alzheimer’s disease. Arch Neurol. 1985;42:1097-1105.
2. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183-194.
3. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol. 2005;62:1160-1163.
4. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia-meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119:252-265.
5. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60:652-656.
6. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid (beta) amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66:382-389.
7. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx. 2004;1:213-225.
8. Blennow K. CSF biomarkers for mild cognitive impairment. J Intern Med. 2004;256:224-234.
9. De Jong D, Kremer BP, Olde Rikkert MG, Verbeek MM. Current state and future directions of neurochemical biomarkers for Alzheimer’s disease. Clin Chem Lab Med. 2007;45:1421-1434.
10. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8:619-627.
11. Jagust WJ, Mormino EC. Lifespan brain activity, B-amyloid, and Alzheimer’s disease. Trends Cogn Sci. 2011;15:520-526.
12. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62:1087-1095.
13. Stern Y. Cognitive reserve. Neuropsychologia. 2009;47:2015-2028.
14. Brown J, Cooper-Kuhn CM, Kemperman G, Van Praag H, Winkler J, Gage FH. Enriched environment and physical activity stimulate hippocampal but not olfactory bulb neurogenesis. Eur J Neurosci. 2003;17:2042-2046.
15. Lazarov O, Robinson J, Tang YP, et al. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell. 2005;120:701-713.
16. Roe CM, Fagan AM, Williams MM, et al. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology. 2011;76:501-510.
17. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association Workgroup. Alzheimers Dement. 2011;7:263-269.
18. Burin D, Jorge RE, Arizaga RA, Paulsen JS. Estimation of premorbid intelligence: the Word Accentuation Test-Buenos Aires version. J Clin Exp Neuropsychol. 2000;22:677-685.
19. Rami L, Valls-Pedret C, Bartres-Faz D, et al. Cuestionario de reserva cognitiva: valores obtenidos en población anciana sana y con enfermedad de Alzheimer [Cognitive reserve questionnaire. Scores obtained in a healthy elderly population and in one with Alzheimer’s disease]. Rev Neurol. 2011;52:195-201. Spanish.
20. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
21. Wechsler D. Wechsler Memory Scale Revised. San Antonio, TX, USA: Psychological Corporation; 1987.
22. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
23. Rosen W, Mohs R, Davis K. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984;141:1356-1364.
24. Rey A. [L‘Examen Clinique en Psychologie]. Paris, France: Presses Universitaires de France; 1964. French.
25. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695-699.
26. Goodglass H, Kaplan E. The Assessment of Aphasia and Related Disorders. 2nd ed, Philadelphia, PA, USA: Lea & Febiger; 1983.
27. Morris JC, Heyman A, Mohs RC, et al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology. 1989;39:1159-1165.
28. Reitan RM. Validity of the Trail-Making Test as an indication of organic brain damage. Percept Mot Skills. 1958;271-276.
29. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Philadelphia, PA, USA: Lea & Febiger; 1983.
30. Blennow K, Zetterberg H. Cerebrospinal fluid biomarkers for Alzheimer’s disease. J Alzheimers Dis. 2009;18:413-417.
31. Stern Y, Alexander GE, Prohovnik I, Mayeux R. Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer’s disease. Ann Neurol. 1992;32:371-375.
32. Rolstad S, Nordlund A, Eckerström C, Gustavsson MH, Zetterberg H, Wallin A. Cognitive reserve in relation to abeta42 in patients converting from MCI to dementia-a follow-up report. Dement Geriatr Cogn Disord. 2009;28:110-115.
33. Kamenetz F, Tomita T, Hsieh H, et al. APP processing and synaptic function. Neuron. 2003;37:925-937.
34. Cirrito JR, Yamada KA, Finn MB, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913-922.
35. Landau SM, Marks SM, Mormino EM, et al. Association of lifetime cognitive engagement and low B-amyloid deposition. Arch Neurol. 2012;69:623-629.
36. Liang KY, Mintun MA, Fagan AM, et al. Exercise and Alzheimer’s disease biomarkers in cognitively normal older adults. Ann Neurol. 2010;68:311-318.
37. Bennett DA, Schneider JA, Wilson RS, et al. Education modifies the association of amyloid but not tangles with cognitive function. Neurology. 2005;65:953-955.